Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,465 matching trials from the live ClinicalTrials.gov search.
Conditions
Ovarian Epithelial Carcinoma
Interventions
PD0332991
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Locally Advanced or Metastatic Solid Tumor
Interventions
Rebastinib, Carboplatin
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Ovarian Reserve After Cancer: Longitudinal Effects

NCT02467231
Conditions
Effects of Chemotherapy, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
11 Years to 35 Years · Female only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 2 Interventional Results available

Salvage Ovarian FANG™ Vaccine + Carboplatinum

NCT01867086
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Vigil™ Vaccine, Carboplatinum, Carboplatinum and Taxol
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
REPS w/BANDS
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Conditions
Ovarian Cancer
Interventions
INCB123667
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
38
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 35 more
Conditions
Ovarian Cancer
Interventions
carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
Conditions
Ovarian Cancer
Interventions
becatecarin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Not listed Not applicable Interventional Accepts healthy volunteers

PCOS & Insulin Resistance Exercise Study

NCT02303470
Conditions
Polycystic Ovary Syndrome, Insulin Resistance
Interventions
Vigorous Exercise, Moderate Exercise
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Ovarian Cancer Recurrent
Interventions
Ombrabulin (AVE8062), Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Burbank, California • New Haven, Connecticut • Fort Meyers, Florida + 2 more
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions
ONM-100
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas
Terminated No phase listed Observational Accepts healthy volunteers

Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome

NCT01615562
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
Interventions
TXA127, Placebo
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 3 more
Completed No phase listed Observational Accepts healthy volunteers

Blood Spot Self-administered Test and Assay

NCT03840824
Conditions
Dysfunction; Endocrine, Effects of Chemotherapy, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting Phase 1 Interventional

Study of NTB-928 in R/R OC

NCT07690189
Conditions
Relapsed/Refractory Ovarian Carcinoma
Interventions
NTB-928
Drug
Lead sponsor
TeneoSeven, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Irinotecan, Bevacizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
New York, New York
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Leuprolide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Alemtuzumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Ovarian Cancer
Interventions
Docetaxel, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
19
States / cities
Fort Myers, Florida • Jupiter, Florida • Orlando, Florida + 16 more
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Dietary Restriction, Exercise Training
Drug · Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
gefitinib
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 43 more
Conditions
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Cancer
Interventions
Dasatinib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
227
States / cities
Anchorage, Alaska • Auburn, California • Berkeley, California + 154 more